Acetic Acid

Acetic Acid

SCHEMBL442951

CC(=O)O.CCCCS(=O)(=O)O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 known ✓ P30556 1/20 0.39
ESR1 known ✓ P03372 1/20 0.37
EPHX2 P34913 1/20 0.44
APP P05067 2/20 0.44
ALDH1A1 P00352 3/20 0.39
HSD17B10 Q99714 2/20 0.39
NPC1 O15118 1/20 0.39
S1PR2 O95136 1/20 0.39
S1PR4 O95977 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
XBP1 P17861 1/20 0.39
S1PR1 P21453 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL11049476 0.93 EPHX2 (0.51) EPHX2APPALDH1A1HSD17B10AKR1B1
Acetic Acid SCHEMBL29064775 0.91 EPHX2 (0.54) EPHX2APPALDH1A1HSD17B10GPR84
SCHEMBL31512497 0.89
SCHEMBL10012319 0.89
SCHEMBL5015 0.89
Acetic Acid SCHEMBL28884856 0.89 EPHX2 (0.53) EPHX2ALDH1A1HSD17B10GPR84PPARG
Acetic Acid SCHEMBL29039147 0.89 EPHX2 (0.53) EPHX2ALDH1A1HSD17B10GPR84PPARG
Acetic Acid SCHEMBL28884855 0.89 EPHX2 (0.53) EPHX2ALDH1A1HSD17B10GPR84PPARG
Benzene SCHEMBL27514240 0.87 APP (0.46) EPHX2APPALDH1A1HSD17B10NPC1
Phosphine SCHEMBL2572785 0.87

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 386 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305624-B1 Self-degradable explosive device MAXAMCORP HOLDING SL (ES) 2017-09-27 EP claimed
US-8585841-B2 Systems and methods for chemical and/or mechanical remediation of nitro compounds and nitrate esters MAXAMCORP HOLDING S.L. (ES) 2013-11-19 US claimed
US-8529955-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-09-10 US claimed
US-8440232-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2013-05-14 US claimed
EP-2445852-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS Maxamcorp Holding, S.L. (ES) 2012-05-02 EP claimed
US-20120064168-A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABEPENTIN DOSAGE DEPOMED, INC. (US) 2012-03-15 US claimed
US-8119166-B2 Methods of treatment using a gastric retained gabapentin dosage DEPOMED, INC. (US) 2012-02-21 US claimed
US-20120027823-A1 METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE DEPOMED, INC. (US) 2012-02-02 US claimed
EP-2305624-A1 Self-degradable explosive formulations Maxamcorp Holding, S.L. (ES) 2011-04-06 EP claimed
US-20110041718-A1 SYSTEMS AND METHODS FOR CHEMICAL AND/OR MECHANICAL REMEDIATION OF NITRO COMPOUNDS AND NITRATE ESTERS MAXAMCORP HOLDING S.L. (ES) 2011-02-24 US claimed
WO-2004112746-A1 CONTROLLED RELEASE-DRUG DELIVERY SYSTEM FOR ORAL ADMINISTRATION KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2004-12-29 WO claimed
US-20040175428-A1 Controlled release by extrusion of solid amorphous dispersions of drugs PFIZER INC. 2004-09-09 US claimed
US-20040137156-A1 Coated solid dosage form and method for preparing same LEE ERNEST J 2004-07-15 US claimed
US-6706283-B1 INCREASING BIOAVAILABILITY OF SPARINGLY WATER SOLUBLE ACTIVE INGREDIENTS; CONTROLLED INFLUX OF WATER TO CORE USING NON-DISSOLVING, NONERODING COATING PFIZER INC 2004-03-16 US claimed
WO-2004010982-A1 METHOD OF PREPARING SOLID DOSAGE FORMS COATED IN TWO LAYERS COMPRISING A WATER-INSOLUBLE POLYMER AND A WATER-SOLUBLE PORE FORMER PHARMACIA CORPORATION (US) 2004-02-05 WO claimed
US-6365185-B1 ORAL TABLET FOR DELIVERING BENEFICIAL AGENT TO MAMMAL COMPRISING CORE COMPARTMENT HAVING BENEFICIAL AGENT SURROUNDED BY UNITARY SELF-DESTRUCTING SHELL COMPRISING PLURALITY OF DISINTEGRANT PARTICLES DISPERSED WITHIN SEMIPERMEABLE MATRIX UNIVERSITY OF CINCINNATI 2002-04-02 US claimed
EP-1027888-A2 Osmotic system for delivery of solid amorphous dispersions of drugs Pfizer Products Inc. (US) 2000-08-16 EP claimed
US-5612059-A CELLULOSE DERIVATIVE, DRUG DELIVERY PFIZER INC. (US) 1997-03-18 US claimed
US-5458887-A OF AN OSMOTIC CORE CONTAINING A DRUG AND A WATER SWELLABLE COMPONENT AND A WATER RESISTANT POLYMER COATING CONTAINING A COMPOUND WHICH DISSOLVES IN GASTROINTESTINAL FLUID ANDRX PHARMACEUTICALS, INC. (US) 1995-10-17 US claimed
US-4761289-A Sustained release implant and method for preparing same INTERNATIONAL MINERALS & CHEMICAL CORP. (US) 1988-08-02 US claimed